Необязательная аналитика продукта
С вашего разрешения мы используем ограниченную аналитику с защитой конфиденциальности, чтобы понять, какие исследовательские сценарии работают. Мы не используем рекламные трекеры или запись сеансов. Этот выбор можно изменить в настройках. Прочитайте Политику конфиденциальности.
Corteva Inc.'s published Strong Buy conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $8.0B | |
|---|---|---|
| Shares out | 667.2M | |
| P/E (forward) | 19.1x | |
| Dividend | $0.13 (1.16%) | |
| Volume | 14,482,667 | |
| Beta | 0.58 |
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | P5 | Trend |
|---|---|---|---|---|---|---|
| Period | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | Trend |
| Revenue | $15.66B | $17.46B | $17.23B | $16.91B | $17.40B | +2.7% |
| Gross profit | $6.44B | $7.02B | $17.23B | $7.38B | $8.23B | +6.3% |
| Operating income | $2.38B | $1.51B | $941.0M | $1.51B | $1.87B | -5.8% |
| Net income | $1.76B | $1.15B | $735.0M | $907.0M | $1.09B | -11.2% |
| EPS (diluted) | $2.37 | $1.58 | $1.03 | $1.30 | $1.60 | -9.4% |
| EBITDA | $3.62B | $2.73B | $941.0M | $2.74B | $3.07B | -4.0% |
| R&D | $1.19B | $1.22B | $1.34B | $1.40B | $1.47B | +5.6% |
| SG&A | $3.21B | $3.17B | $3.18B | $3.20B | $3.49B | +2.1% |
Recent company headlines from major financial publishers.
Corteva executes on its core operational strategy: Seed segment trait out-licensing continues tracking three years ahead of plan, offsetting broader crop price softening. Crop Protection new patented products touch $2.0B in FY2026, neutralizing mid-single-digit price declines in legacy chemistries. Latin American growth moderates to low-single-digit rates due to tight farmer credit. Cash generation remains robust, funding steady share repurchases and balance sheet health.
Proprietary seed trait licensing expands ahead of schedule across third-party seed networks, driving substantial margin expansion. Patented crop protection molecules and biologicals exceed commercial launch targets, capturing market share from distressed commodity competitors. Brazilian safrinha corn planted area expands briskly, lifting Latin American revenue growth above historical trend and driving diluted EPS to the high end of analyst estimates.
| Ke ↓ / g → | 2.0% | 2.3% | 2.5% | 2.8% | 3.0% |
|---|---|---|---|---|---|
| 5.5% | $56.4 | $58.6 | $61.2 | $64.2 | $67.7 |
| 6.0% | $52.0 | $53.6 | $55.5 | $57.6 | $60.1 |
| 6.5% | $48.4 | $49.7 | $51.7 | $52.7 | $54.6 |
| 7.0% | $45.4 | $46.5 | $47.6 | $48.9 | $50.3 |
| 7.5% | $43.0 | $43.8 | $44.7 | $45.7 | $46.8 |
Upcoming earnings date and setup when available.
Рейтинг, который имело опубликованное в каждом месяце издание исследования. Рейтинг сравнивает цену на дату анализа со справедливой стоимостью; он не показывает, оправдалась ли оценка.
| Год | янв. | февр. | март | апр. | май | июнь | июль | авг. | сент. | окт. | нояб. | дек. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |
